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The phorbol ester TPA (12-O-tetrad~anoyl phorboI-13-acetate) causes a dose-de~ndent inhibition of the 
glu~agon-stimulated a enylate cyclase activity expressed in plasma membranes isolated from TPA-treated 
hypatocytes. However, no observable inhibitory effect of TPA on adenylate cyclase activity was observed 
in cells which had been exposed to glucagon for 5 min, prior to isolation, to desensitise adenylate cyclase. 
The degree of inhibition of adenylate cyclase elicited by both glucagon desensitisation and TPA treatment 
of hepatocytes was identical. Pre-treatment of hepatocytes with TPA was also found to prevent glucagon 
from blocking insulin’s activation of the peripheral plasma membrane cyclic AMP phosphodiesterase in in- 
tact hepatocytes. TPA treatment also inhibited the ability of cholera toxin to activate the peripheral cyclic 
AMP phosphodiesterase in intact hepatocytes. It is suggested that in these particular instances TPA and 
glucagon elicit mutually exclusive processes rather than TPA mimicking glucagon desensitisation per se. 
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1. INTRODUCTION 
TPA (12-O-tetradecanoyl phorbol-l3-acetate) is 
a potent tumour agent [l]. It expresses the ability 
to activate the ubiquitous enzyme protein kinase 
C, a route whereby it might exert at least certain of 
its actions on target cells [2]. 
Glucagon binds to high-affinity receptors on the 
liver cell surface. These interact with the 
stimulatory guanine nucleotide regulatory protein 
Ns, which in turn interacts with, and activates, the 
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catalytic unit of adenylate cyclase [3,4]. However, 
in intact hepatocytes, glucagon also causes the 
rapid desensitisation of adenylate cyclase [5-81. 
This desensitisation isthought to result from either 
a modification of N, [5,6] or the indirect activation 
[5,7] of N,, a distinct guanine nucleotide regulatory 
protein which mediates the action of inhibitory 
hormones on adenylate cyclase (see [4]). 
Treatment of hepatocytes with glucagon also in- 
duces an ‘insulin-resistant’ state which is selective 
to certain actions of insulin [9,10]. In particular, it 
prevents insulin from activating a distinct, high- 
affinity, peripheral plasma membrane AMP 
phosphodiesterase 191. The process by which 
glucagon elicits such an action is cyclic AMP in- 
dependent [9] and has the same time and dose 
dependence as that process by which glucagon 
elicits the desensitisation of adenylate cyclase [5,8]. 
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Furthermore, both of these actions of glucagon are 
obliterated by the presence of adenosine and 
N6-phenylisopropyladenosine (PIA) functioning 
through high-affinity ‘R’-type receptors [ 111. 
We have demonstrated previously that TPA in- 
hibits glucagon-stimulated adenylate cyclase activi- 
ty in hepatocytes through a mechanism thought to 
involve the action of protein kinase C [12]. This ac- 
tion of TPA was located functionally at the point 
of regulation of adenylate cyclase by guanine 
nucleotide. Here we show that like adenosine and 
PIA [l 11, TPA can prevent the expression of both 
glucagon desensitisation and glucagon’s block of 
the stimulatory action of insulin on the peripheral 
plasma membrane cyclic AMP phosphodiesterase. 
2. MATERIALS AND METHODS 
Hepatocytes from male Sprague-Dawley rats 
(200-300 g) were prepared and incubated as 
described by us [5]. The Krebs-Henseleit incuba- 
tion medium contained 2.5% bovine serum 
albumin and CaC12 at a final concentration of 
2.5 mM. 
A membrane fraction was obtained from these 
hepatocytes as in [10,13] and used for the assay of 
adenylate cyclase activity. This membrane 
preparation was assayed for adenylate cyclase ac- 
tivity basically as described in [lo]. Briefly the in- 
cubation mixture contained final concentrations of 
1.5 mM ATP, 5 mM MgS04, 10 mM theophyl- 
line, 7.4 mg/ml phosphocreatine, 1 mg/ml crea- 
tine kinase and 25 mM triethanolamine HCl at a 
final pH of 7.4. Membranes were present at 1 mg/ 
ml and rates were determined from linear time 
courses obtained over 10 min incubation at 30°C. 
Measurement of cyclic AMP produced utilised a 
muscle binding protein assay performed as de- 
scribed by us in [lo]. 
To assess intracellular cyclic AMP accumula- 
tion, cells (4-5 mg dry wt/ml) were pre-incubated 
for 20 min at 37°C either with isobutylmethylxan- 
thine (IBMX) (10 mm), to inhibit cyclic AMP 
phosphodiesterase (see [5]) or not. After an ap- 
propriate period of incubation, aliquots were 
taken for the determination of intracellular cyclic 
AMP content as in [5]. 
Assessment of activation of the plasma mem- 
brane cyclic AMP phosphodiesterase activity by 
insulin was made as before [9,14] using the rapid 
Percoll fractionation procedure to separate out the 
various subcellular components of the hepa- 
tocytes. As before it was crucial to ensure a good 
separation of the plasma membranes from the en- 
doplasmic reticulum fractions otherwise the sig- 
nificant activity in those fractions obscured the ac- 
tivation of the plasma membrane enzyme. This 
was ensured by ‘calibrating’ each batch of Percoll 
to give marker enzyme separation profiles as 
detailed previously [9]. Such calibration involved 
adjusting the speed of centrifugation in order to 
obtain the desired separation profile [9]. 
Cyclic AMP phosphodiesterase activity was 
determined at a final substrate concentration of 
100 nM cyclic AMP using a t-step assay procedure 
[ 151 as modified and described in some detail by us 
[ 161. Initial rates were taken from linear time 
courses. 
TPA, bovine serum albumin, theophylline and 
IBMX were from Sigma, Poole, England. Creatine 
kinase, phosphocreatine, triethanolamine HCl, 
cyclic AMP, collagenase guanine nucleotides, 
A23187 and all other biochemicals were from 
Boehringer, Lewes, England. Glucagon was a kind 
gift from Dr W.W. Bromer, Eli Lilly & Co., In- 
dianapolis, IN. All general biochemicals were from 
BDH Chemicals, Poole, England. All radio- 
chemicals were from Amersham International, 
Amersham, England. 
3. RESULTS 
Fig.1 demonstrates that the treatment of 
hepatocytes with TPA causes a dose-dependent 
decrease in the glucagon-stimulated adenylate 
cyclase activity expressed in plasma membranes 
isolated from such cells. The degree of inhibition 
elicited by TPA is similar to that observed when 
assessing its interaction by following glucagon- 
stimulated cyclic AMP production in intact 
hepatocytes [12]. We also observed here (fig.1) as 
before [5], that, if hepatocytes were treated with 
glucagon (10e8 M) for 5 min, prior to isolating 
plasma membranes, then a loss/desensitisation of 
the glucagon-stimulated adenylate cyclase activity 
occurred in these membranes. However, we show 
here that the absolute degree of inhibition of 
glucagon-stimulated adenylate cyclase activity 
observed in such glucagon-pretreated cells was 
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Fig. 1. Changes in glucagon stimulated adenylate cyclase 
activity expressed in membranes from hepatocytes 
treated with TPA. Adenylate cyclase activity is expressed 
in pmol/min per mg protein. Hepatocytes were 
incubated at 37°C as described in section 2 with 
increasing concentrations of TPA for a 15 min period 
(0). They were then isolated and a washed membrane 
fraction prepared for the assay of glucagon-stimulated 
adenylate cyclase activity. In some instances (0) 
hepatocytes were subsequently incubated with glucagon 
(10 nM) for 5 min prior to harvesting. No difference in 
the results for the action of TPA in control (glucagon 
absent) experiments was observed if incubations were 
performed for 20 min rather than 15 min. Data are 
shown with SD for 3 separate experiments using 
different cell preparations (n = 3). In each experiment 
adenylate cyclase assays were performed in triplicate. 
constant regardless of the presence of a variety of 
inhibitory concentrations of TPA (fig. 1). 
As before [9], incubation of intact hepatocytes 
with insulin (10 nM) for 5 min led to the activation 
of the peripheral plasma membrane cyclic AMP 
phosphodiesterase. This effect blocked by pre- 
exposure of the cells to glucagon (10 nM) for 
5 min prior to the addition of insulin (table 1). We 
see here, however, that pre-incubation of the cells 
with TPA, whilst having no effect on the plasma 
membrane phosphodiesterase activity observed in 
control and in insulin- and glucagon-treated 
hepatocytes, actually allowed insulin to activate 
this enzyme in hepatocytes which had been pre- 
exposed to glucagon (table 1). TPA pre-treatment 
also decreased the ability of cholera toxin to ac- 
tivate the plasma membrane cyclic AMP 
phosphodiesterase (table 1). 
TPA pre-treatment had no effect (8% dif- 
ference) on the activation of the ‘dense-vesicle’ 
phosphodiesterase that was elicited by insulin, 
glucagon, insulin plus glucagon and cholera toxin. 
Table 1 
The effect of the tumour promoting agent TPA on the 
ability of hormones and cholera toxin to regulate the 
peripheral plasma membrane cyclic AMP phospho- 
diesterase in intact hepatocytes 
Ligand Phosphodiesterase activity 
with respect o control 
(100%) 
Control cells TPA-pre- 
treated cells 
Insulin (10 nM), 5 min 153 jl 9 165 ? 10 
Glucagon (10 nM), 5 min 104 * 2 105+ 2 
Glucagon for 5 min then 
insulin for 5 min 
Cholera toxin (1 g/ml), 
102 1 5 145 * 10 
30 min 157 + 9 127+ 8 
Hepatocyte suspensions (4-5 mg dry wt/ml) were 
incubated for 20 min at 37°C in either the presence or 
absence of TPA (10 ng/ml). They were then exposed 
either to hormones as defined above or to cholera toxin 
prior to harvesting, disruption and assessment of 
changes in activity in various subcellular fractions [9]. 
Incubation with TPA for this period of time did not 
affect the specific activity of the plasma membrane 
phosphodiesterase. This remained at 97 f 12% of that 
observed in control studies. All data are shown + SD 
taken for 3 separate xperiments (n = 3) using different 
cell preparations. As before triplicate cyclic AMP 
phosphodiesterase assays were performed on the 
gradients 
This particular enzyme is associated with an in- 
tracellular membrane fraction [9] and is activated 
by both glucagon and insulin. It has been shown to 
be activated by insulin through a route which is 
distinct from that used to activate the plasma 
membrane enzyme [14]. These results are consis- 
tent with such a conclusion. 
4. DISCUSSION 
We have previously demonstrated that treatment 
of hepatocytes with TPA leads to an inhibition of 
the glucagon-stimulated cyclic AMP accumulation 
that occurs in these cells in the presence of a 
phosphodiesterase inhibitor [ 121. Here, we con- 
firm our conclusion that TPA inhibits adenylate 
cyclase by demonstrating that the glucagon- 
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stimulated adenylate cyclase activity in membranes 
isolated from such TPA-treated cells is indeed 
inhibited. 
Normally, exposure of hepatocytes to glucagon 
for 5 min, prior to membrane isolation, leads to a 
dose-dependent desensitization of glucagon- 
stimulated adenylate cyclase activity in isolated 
membranes [5]. Our present intriguing observation 
is, however, that this cyclic AMP-independent 
[5,8] action of glucagon is completely obliterated 
in TPA pre-treated hepatocytes (fig. 1). Indeed the 
degree of inhibition of glucagon-stimulated 
adenylate cyclase activity by both desensitisation 
and TPA-treatment is comparable (fig.1). This 
suggests that TPA might either mimic glucagon 
desensitisation or elicit a mutually exclusive in- 
hibitory action. 
Now, whatever mechanism elicits glucagon 
desensitisation bears very close relationships as 
regards time and dose dependence to that by which 
glucagon blocks insulin’s stimulation of the 
peripheral plasma membrane cyclic AMP 
phosphodiesterase in intact hepatocytes [5,9]. 
They also both appear to be cyclic AMP- 
independent actions of glucagon [5,9]. Further- 
more adenosine and its analogues [l l] and also 
islet activating protein (pertussis toxin) [17] both 
prevent glucagon desensitisation from occurring 
and prevent glucagon’s blockade on insulin’s ac- 
tivation of the plasma membrane phospho- 
diesterase. This again suggests that these 2 actions 
of glucagon have a common origin. We see here 
(table 1) that TPA acts identically to these agents 
in preventing the glucagon-mediated block of in- 
sulin’s stimulation of the plasma inembrane 
phosphodiesterase. This observation might suggest 
that TPA, in inhibiting adenylate cyclase, does not 
trigger the same process as glucagon desensitisa- 
tion but rather elicits a mutually exclusive action. 
The net effect of this is for TPA to not only mimic 
the degree of inhibition of adenylate cyclase 
elicited by glucagon desensitisation but also to pre- 
vent glucagon’s blockade on insulin’s stimulation 
of the plasma membrane phosphodiesterase. 
Insulin’s stimulation of the plasma membrane 
cyclic AMP phosphodiesterase has been suggested 
to be mediated by a distinct guanine nucleotide 
regulatory protein [9,10,18]. This has been ten- 
tatively identified as a 25 kDa species, called Nins, 
which can be ADP-ribosylated and activated by 
cholera toxin [19]. Whilst elevated cyclic AMP 
concentrations do not activate the plasma mem- 
brane phosphodiesterase, treatment with cholera 
toxin does [9]. This may well be mediated via the 
ribosylation and activation of the 25 kDa protein 
called Nins. We see here that TPA inhibits the 
cholera toxin-mediated activation of the plasma 
membrane phosphodiesterase (table 1). This is 
consistent with our observations that in TPA- 
treated hepatocytes, the ability of cholera toxin to 
ribosylate specifically Nins was markedly reduced 
[ 191, so providing further support to our conten- 
tion [9,10,18] that insulin activates the plasma 
membrane phosphodiesterase through a distinct 
guanine nucleotide regulatory protein called Nins. 
TPA is believed to exert its physiological effects 
through activation of protein kinase C [2]. Whilst 
we [ 121 have presented some evidence which is con- 
sistent with TPA inhibiting adenylate cyclase 
through such a route, the putative target for 
phosphorylation has yet to be identified, although 
it is suggested that the perturbation lies at the level 
of regulation of this enzyme by guanine 
nucleotides. These studies pose the possibility that 
the putative Nins may be a substrate for 
phosphorylation. In this latter aspect, it is of in- 
terest that phorbol esters can stimulate the 
phosphorylation of the insulin receptor itself [20] 
and have also been shown to modify other actions 
of insulin such as lipogenesis [21]. 
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